Biopharmaceutical company Absci Corp. (ABSI) announced Tuesday the appointment of Ransi Somaratne as Chief Medical Officer. A former Vertex executive, Somaratne will spearhead the clinical development strategy and execution for Abscis expanding pipeline of AI-designed therapeutics.
Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen.
Alongside Somaratne's appointment, Absci announced the retirement of Chief Innovation Officer Andreas Busch. He was a driving force in building Abscis AI-designed therapeutics pipeline, most notably in the discovery and development of ABS-201.
Busch will transition from his executive duties on March 31, 2026 to co-chair Abscis Scientific Advisory Board, where he will continue to provide scientific and strategic advice and oversight to the company.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.